MAPT and Alzheimer disease: Our findings demonstrate that postmenopausal women with the most severe AD biomarkers (i.e., low ratios of Aβ42/40 or Aβ42/p-tau 181) benefit more from higher levels of endogenous estrogens, compared to women with less severe AD biomarker ratios.